Notice of Proposed Sale · 144
Pharvaris N.V.
PHVSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- PHARVARIS N.V.
- Issuer CIK
- 0001830487
- SEC file number
- 001-40010
- Phone
- 31 (0)71 2036 410
- Person for whose account securities are to be sold
- ROBERT R. GLASSMAN
- Relationships to issuer
- Director
- Street
- Emmy Noetherweg 2
- City
- Leiden
- State / country code
- P7
- Postal code
- 2333 BK
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 8,000 | 300,396.00 | 70,204,506 | 09/09/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 09/09/2026 | Stock Option Exercise | Issuer | 8,000 | N | 09/09/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 09/09/2026
- Signed
- /s/ Robert Howard Glassman
Company context
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. For more information, visit https://pharvaris.com/.
Current securities
Recent company filings
- SCHEDULE 13G/A - filed by VIKING GLOBAL INVESTORS LP regarding Pharvaris N.V.Nov 16, 2026
- SCHEDULE 13G - filed by WELLINGTON MANAGEMENT GROUP LLP regarding Pharvaris N.V.Nov 16, 2026
- SCHEDULE 13G/A - filed by GENERAL ATLANTIC, L.P. regarding Pharvaris N.V.Nov 13, 2026
- 6-K filingNov 12, 2026
- 144 filingSep 23, 2026